Notice: This company has been marked as potentially delisted and may not be actively trading. Apexigen (APGN) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition CompletedSeptember 7, 2023 | seekingalpha.comTrading was temporarily halted for "APGN" at 07:08 PM with a stated reason of "News pending."August 23, 2023 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGNAugust 11, 2023 | markets.businessinsider.comApexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJune 3, 2023 | finance.yahoo.comEF Hutton Reiterates Apexigen (APGN) Hold RecommendationMay 27, 2023 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGNMay 24, 2023 | markets.businessinsider.comEF Hutton Maintains Apexigen (APGN) Buy RecommendationMay 17, 2023 | msn.comAPG SGA S.A.May 16, 2023 | wsj.comAre Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?March 3, 2023 | finance.yahoo.comAre Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?March 3, 2023 | finance.yahoo.comApexigen Announces Review of Strategic Alternatives and RestructuringFebruary 27, 2023 | finance.yahoo.comApexigen Announces Approximately $2.8 Million Private Placement FinancingJanuary 24, 2023 | finance.yahoo.comWhy Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving PremarketJanuary 23, 2023 | msn.comApexigen Touts New Positive Sotigalimab Data Showing Expanded Anti-Tumor ResponsesJanuary 19, 2023 | finance.yahoo.comThinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?January 19, 2023 | benzinga.comApexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023January 19, 2023 | finance.yahoo.comApexigen Shares Halted On Circuit Breaker To The Upside, Stock Now Up 140.5%January 11, 2023 | benzinga.comTrading was temporarily halted for "APGN" at 03:01 PM with a stated reason of "LULD pause."January 9, 2023 | marketbeat.comTrading was temporarily halted for "APGN" at 09:01 AM with a stated reason of "LULD pause."January 9, 2023 | marketbeat.comTrading was temporarily halted for "APGN" at 09:01 AM with a stated reason of "LULD pause."January 9, 2023 | marketbeat.comApexigen Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 15, 2022 | finance.yahoo.comApexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual MeetingNovember 11, 2022 | finance.yahoo.comHow biotech companies are building drug pipelines with PIPEsNovember 4, 2022 | bizjournals.comWall Street Set to Open Lower as Higher-Than-Expected UK Inflation Rattles InvestorsOctober 19, 2022 | msn.comApexigen, Inc. (APGN)October 6, 2022 | ca.finance.yahoo.comApexigen's Shares Fall After Data From Gastric Cancer CandidateSeptember 12, 2022 | finance.yahoo.comApexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022September 10, 2022 | finance.yahoo.comApexigen to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 7, 2022 | finance.yahoo.comApexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022September 5, 2022 | finance.yahoo.comApexigen, Inc. Rings the Closing BellSeptember 2, 2022 | nasdaq.comTrading was temporarily halted for "APGN" at 10:08 AM with a stated reason of "LULD pause." Trading set to resume at 10:08 AM. August 26, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 02:08 PM with a stated reason of "LULD pause." Trading set to resume at 02:08 PM. August 19, 2022 | marketbeat.comApexigen to Participate in the 2022 Wedbush PacGrow Healthcare ConferenceAugust 16, 2022 | finance.yahoo.comIs Apexigen (NASDAQ:APGN) In A Good Position To Deliver On Growth Plans?August 16, 2022 | finance.yahoo.comTrading was temporarily halted for "APGN" at 11:08 AM with a stated reason of "LULD pause."August 12, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 11:08 AM with a stated reason of "LULD pause."August 12, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 02:08 PM with a stated reason of "LULD pause."August 2, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 10:08 AM with a stated reason of "LULD pause."August 1, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 10:08 AM with a stated reason of "LULD pause."August 1, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 10:08 AM with a stated reason of "LULD pause."August 1, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 10:08 AM with a stated reason of "LULD pause."August 1, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 09:08 AM with a stated reason of "LULD pause."August 1, 2022 | marketbeat.comTrading was temporarily halted for "APGN" at 09:08 AM with a stated reason of "LULD pause."August 1, 2022 | marketbeat.com Get Apexigen News Delivered to You Automatically Sign up to receive the latest news and ratings for APGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Central Bank Abandons USD (Ad)You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! APGN Media Mentions By Week APGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGN News Sentiment▼0.000.48▲Average Medical News Sentiment APGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGN Articles This Week▼00▲APGN Articles Average Week Get Apexigen News Delivered to You Automatically Sign up to receive the latest news and ratings for APGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LUMO News Today OSTX News Today RAPT News Today NXTC News Today CARM News Today FGEN News Today LEXX News Today CLNN News Today LTRN News Today ACST News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGN) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apexigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apexigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
